Inhibition of UDP‐glucuronosyltransferase by Aglycons of Natural Glucuronides in Kampo Medicines Using SN‐38 as a Substrate

Japanese Journal of Cancer Research

Volumn 86, Issue 10, 1995, Pages 985-989

  Yokoi, Tsuyoshi ^a   Narita, Mikako ^a   Nagai, Eiichi ^b   Hagiwara, Hisao ^c   Aburada, Masaki ^d   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^d Ami Cho ^*  (Japan)

Author keywords

1 Naphthol; Baicalein Glycyrrhetic acid; Luteolin; SN 38 glucuronide

Indexed keywords

1 NAPHTHOL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BAICALEIN; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLYCYRRHETINIC ACID; IRINOTECAN; KAMPO; LUTEOLIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 85004809753     PISSN: 09105050     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1995.tb03011.x     Document Type: Article

References (20)

1. Nonlinear pharmacokinetics of CPT‐11 in rats
2. Antitumor activity of 7‐ethyl‐10‐[4‐(l‐piperidino)‐l‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors
3. Antitumor effect of CPT‐11, a new derivative of camptothecin, against pleotropic drug‐resistant tumors in vitro and in vivo
4. Antitumor activity of CPT‐11 against rat Walker 256 carcinoma
5. Characterization of a mammalian mutant with a camptothecin‐resistant DNA topoisomerasel
6. Studies on the metabolic fate of CPT‐11 (2), pharmacokinetics in rats following a single intravenous dose (2), metabolites pattern in serum, liver, kidney and intestinal tissue
7. Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse
8. An early phase II study of CPT‐11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma
9. Relationship between development of diarrhea and the concentration of SN‐38, an active metabolite of CPT‐11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT‐11
10. Scientific reevaluation of Kampo prescriptions using modern technology
11. UDP‐glucuronosyltransferase activities. Guidelines for consistent interim terminology and assay conditions
12. Effects of lyophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome 65 and cytochrome P‐450 and aniline‐induced P‐450 difference spectrum
13. Protein measurement with the Folin phenol reagent
14. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
15. Characterization of microsomal bilirubin and p‐nitrophenol uridine diphosphate glucuronosyltransferase activities in human liver: a comparison with rat liver
16. Phase I study and pharmacokinetics of CPT‐11 with 5‐day continuous infusion
17. Phase I clinical study of CPT‐11
18. Intracellular roles of SN‐38, a metabolite of the camptothecin derivative CPT‐11 in the antitumor eifect of CPT‐11
19. Inhibition of β‐glucuronidase by natural glucuronidases of Kampo medicines using glucu‐ronide of SN‐38 (7‐ethyl‐10‐hydroxycamptothecin) as a substrate